Zealand Pharma Enters Agreement With Dcai to Use Gefion AI Supercomputer to Accelerate Drug Discovery and Support Metabolic Frontier 2030 Strategy
Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy
-
Access to Gefion, Denmark’s flagship AI supercomputer, gives Zealand Pharma access to unprecedented computational power, enabling large-scale modeling, prediction, and optimization of drug candidates
-
Agreement will support Zealand Pharma’s Metabolic Frontier 2030 strategy to deliver five launches, +10 clinical pipeline programs, and industry-leading cycle times from idea to clinic by 2030
Zealand Pharma A/S, a biotechnology company transforming the future of metabolic health, announces an agreement with DCAI, an AI infrastructure company which operates Gefion, Denmark’s supercomputer, to strengthen and accelerate drug discovery.
Working with DCAI, Zealand Pharma will be able to integrate enterprise-scale artificial intelligence into its drug discovery and development workflows, generating proprietary insights that further enhance the quality and efficiency of medicine creation as the Company executes its Metabolic Frontier 2030 strategy.
Gefion’s state-of-the-art infrastructure provides Zealand Pharma with scalable, flexible computational power tailored to the specific requirements of each research project. With more than 1,500 NVIDIA GPUs powered entirely by renewable energy – and combined with the Company’s more than 25 years of peptide research expertise – this capability enables large-scale protein–peptide simulations with unprecedented computational capacity. The platform supports advanced characterization, simulation, and generative AI modeling for drug discovery and design.
“By integrating DCAI’s powerful AI infrastructure into our research workflows, Zealand Pharma is fundamentally transforming our approach to peptide discovery and design,” said Utpal Singh, Chief Scientific Officer of Zealand Pharma. “Gefion’s computational power will generate new insights that augment the expertise of our scientists. These enhanced capabilities directly support our Metabolic Frontier 2030 strategy, including our ambition to deliver more than 10 clinical programs and achieve industry-leading cycle times from idea to clinic by 2030. Combined with our deep peptide expertise, this computationally driven approach positions Zealand Pharma to lead the next generation of metabolic health innovation while maintaining the rigorous scientific standards that define our leadership in peptide therapeutics.”
Working with Zealand Pharma marks a significant important milestone for DCAI as we continue to accelerate life sciences and biotechnology through impactful AI” said Nadia Carlsten, CEO of DCAI. “It’s rewarding to see innovative customers use our AI capabilities and translate them into measurable scientific and clinical outcomes: by providing scalable AI computing for Zealand Pharma’s peptide discovery initiatives, we can help reduce development timelines and contribute to innovative metabolic treatments for patients around the world.”
Also Read: The End Of Serendipity: What Happens When AI Predicts Every Choice?
[To share your insights with us, please write to psen@itechseries.com]
Comments are closed.